
US lawmakers launch investigation into FDA approval and price of new Alzheimer's drug
CNN
Two House committees have launched an investigation into the approval and pricing of the Alzheimer's disease drug aducanumab, made by the company Biogen and sold under the brand name Aduhelm.
The US Food and Drug Administration approved the drug earlier this month under its "accelerated approval" program, although an FDA advisory committee concluded last year that there was not enough evidence to support the effectiveness of the treatment.More Related News













